Treatment of children with high grade glioma with nimotuzumab A 5-year institutional experience

mAbs

Volumn 5, Issue 2, 2013, Pages 202-207

  Cabanas, Ricardo ^a   Saurez, Giselle ^b   Rios, Martha ^a   Alert, Jose ^c   Reyes, Adnolys ^d   Valdes, Jose ^a   Gonzalez, Maria C ^a   Pedrayes, Jorge L ^a   Avila, Melba ^a   Herrera, Raiza ^a   Infante, Mariela ^a   Echevarria, Ernesto ^a   Moreno, Myrna ^a   Luaces, Patricia Lorenzo ^b   Ramos, Tania Crombet ^b  

^a Juan Manuel Marquez Pediatric Hospital   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^d INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA   (Cuba)

Author keywords

Anaplastic astrocytoma; Children glioma; Glioblastoma multiforme; High grade glioma; Monoclonal antibody; Nimotuzumab

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G1 ANTIBODY; NIMOTUZUMAB; PREDNISONE; PROCARBAZINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPASSIONATE USE; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; MITOSIS RATE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PRESCHOOL CHILD; RASH; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING;

ANAPLASTIC ASTROCYTOMA; CHILDREN GLIOMA; GLIOBLASTOMA MULTIFORME; HIGH GRADE GLIOMA; MONOCLONAL ANTIBODY; NIMOTUZUMAB;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; GLIOMA; HUMANS; MALE; NEOPLASM GRADING; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84876520122     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22970     Document Type: Article

References (33)

1. Lashkari HP, Saso S, Moreno L, Athanasiou T, Zacharoulis S. Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. J Neurooncol 2011; 105: 135-47; PMID:21748491; http://dx.doi.org/10.1007/s11060-011-0657-7
2. Khatua S, Sadighi ZS, Pearlman ML, Bochare S, Vats TS. Brain tumors in children-current therapies and newer directions. Indian J Pediatr 2012; 79: 922-7; PMID:22294272; http://dx.doi.org/10.1007/s12098- 012-0689-9
3. Anuario Estadístico de Cuba 2010. Incidencia de cáncer en menores de 15 años según grupos diagnósticos y edad año 2007. Disponible en: http//bvs.sld.cu/ cgi-bin/wxis/anuario
4. MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neuro Oncol 2011; 13: 1049-58; PMID:21784756; http://dx.doi.org/10.1093/neuonc/nor092
5. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011; 13: 317-23; PMID:21339192; http://dx.doi.org/10.1093/neuonc/noq191
6. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010; 28: 3048-53; PMID:20479391; http://dx.doi.org/10.1200/ JCO.2009.25.6941
7. Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 2010; 116: 705-12; PMID:19957326; http://dx.doi.org/10.1002/cncr.24730
8. Gottardo NG, Gajjar A. Chemotherapy for malignant brain tumors of childhood. J Child Neurol 2008; 23: 1149-59; PMID:18952581; http://dx.doi.org/ 10.1177/0883073808321765
9. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006; 7: 241-8; PMID:16510333; http://dx.doi.org/10.1016/S1470-2045(06)70615-5
10. Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg 2011; 66: 10-7; PMID:21485758
11. Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999; 5: 1786-92; PMID:10430083
12. Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 2009; 11: 274-80; PMID:18981259; http://dx.doi.org/10.1215/15228517-2008-092
13. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28: 4221-7; PMID:20713864; http://dx.doi.org/10.1200/JCO.2010.28.4687
14. Cui Y, Zhao JZ. Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them. Zhonghua Yi Xue Za Zhi 2008; 88: 3356-8; PMID:19257969
15. Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 2009; 15: 5753-61; PMID:19737945; http://dx.doi.org/10.1158/1078-0432.CCR-08-3210
16. Liang ML, Ma J, Ho M, Solomon L, Bouffet E, Rutka JT, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol 2008; 87: 247-53; PMID:18193393; http://dx.doi.org/10.1007/s11060- 007-9513-1
17. Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011; 11: 247-56; PMID:21171927; http://dx.doi.org/10.1517/1471259 8.2011.546341
18. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11: 373-82; PMID:21150278; http://dx.doi.org/10.4161/cbt.11.4.14097
19. Ramos-Suzarte M, Rodríguez N, Oliva JP, Iznaga- Escobar N, Perera A, Morales A, et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 1999; 40: 768-75; PMID:10319748
20. Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006; 5: 375-9; PMID:16575203; http://dx.doi.org/10.4161/ cbt.5.4.2522
21. Crombet T, Torres O, Rodríguez V, Menéndez A, Stevenson A, Ramos M, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001; 20: 131-6; PMID:11394532; http://dx.doi.org/10.1089/02724570152057634
22. Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 2006
23. Bode U, Windelberg M, Massimino M, Khuhlaeva E, Warmuth-Metz M, Kortmann RD. Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. J Clin Oncol 2008; 26:2058; PMID:18421063
24. Massimino M, Biassoni V, Gandola L, Schiavello E, Pecori E, Bach F. Nimotuzumab and vinorelbine concomitantly to radiation and as maintenance for diffuse pontine glioma in childhood: Results from a series of 12 patients. J Clin Oncol 2011; 26:9557
25. Narayana A, Perretta D, Kunnakkat S, Gruber D, Golfinos J, Parker E, et al. Invasion is not an independent prognostic factor in high-grade glioma. J Cancer Res Ther 2011; 7: 331-5; PMID:22044816; http://dx.doi.org/10.4103/0973- 1482.87039
26. Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, et al.; American Society of Clinical Oncology; European Society of Medical Oncology. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011; 16: 228-38; PMID:21273511; http://dx.doi.org/10.1634/theoncologist. 2010-0298
27. Pomerantz RG, Mirvish ED, Geskin LJ. Cutaneous reactions to epidermal growth factor receptor inhibitors. J Drugs Dermatol 2010; 9: 1229-34; PMID:20941947
28. Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, et al.; Comité Pharmacologie of the SFCE. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer 2012; 59: 34-8; PMID:22287258; http://dx.doi.org/ 10.1002/ pbc.24066
29. Gururangan S, Chi SN, Young Poussaint T, Onar- Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28: 3069-75; PMID:20479404; http://dx.doi.org/10.1200/JCO.2009.26.8789
30. Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, et al. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol 2011; 103: 673-80; PMID:21038110; http://dx.doi.org/10.1007/s11060- 010-0444-x
31. Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol 2010; 12: 985-90; PMID:20363768; http://dx.doi.org/10.1093/neuonc/noq033
32. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. In: Sobin LH, editor. International histological classification of tumours. Geneva: Springer-Verlag, 1993: 11-16
33. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-72; PMID:20231676; http://dx.doi.org/10.1200/JCO.2009.26.3541